Fabrice N. Vincent
Partner, San Francisco Office
email
415 956-1000
vcard

“The litigation process is often confusing. We care for our clients, keep their best interests first and foremost and assure they are educated and empowered so they can make informed decisions.”
Fabrice N. Vincent
Fabrice N. Vincent

A partner in our San Francisco office, Fabrice N. Vincent is a tireless and principled advocate for the injured and the families of loved ones who died in personal injury and wrongful death cases. Fabrice’s cases include JUUL vaping injury claims, baby formula injury and death claims, hair relaxer cancer claims, aviation accidents, auto and recreational vehicle accidents, cases arising from defective infant and consumer products, dangerous prescription drugs, and faulty medical devices.

Fabrice’s practice also includes cases involving environmental toxic exposures, medical malpractice, and international and human rights violations. In many of the cases Fabrice has prosecuted, he has assisted our clients in persuading corporate defendants to issue recalls or improve their safety procedures for the protection of all consumers and patients.

Fabrice played a pivotal role in the firm’s representation of patients injured by the diet drugs fenfluramine (sold as Pondimin) and dexfenfluramine (sold as Redux), which resulted in a $4.75 billion settlement for those who developed cardiac valve damage or the often fatal condition of Primary Pulmonary Hypertension after taking Pondimin or Redux. Fabrice successfully represented scores of injured patients in individual lawsuits. Fabrice has been recognized by Super Lawyers magazine as a Northern California Super and has written extensively on current issues in litigation.

Long form bio (click to open pdf).

  • Cornell Law School, Ithaca, New York
    J.D. (Cum Laude) – 1992
  • University of California, Berkeley, California
    B.A. – 1989

  • California, 1992
  • California Supreme Court, 1992
  • U.S. Court of Appeals, 9th Circuit, 1992
  • U.S. District Court, Central District of California, 1992
  • U.S. District Court, Eastern District of California, 1992
  • U.S. District Court, Northern District of California, 1992
  • U.S. District Court, District Court of Colorado, 2019
  • U.S. District Court, Northern District of Illinois Court, 2022
  • U.S. District Court, Eastern District of Michigan, 2020

  • American Association for Justice
  • American Bar Association, Book Committee, Member, 2022
  • American Bar Association, Co-Chair, Business Torts & Unfair Competition Committee, 2022-2023
  • American Bar Association, Co-Chair, Products Liability Committee, 2019
  • American Bar Association, Co-Chair, Class Actions Committee, 2017, 2018
  • Association of Business Trial Lawyers
  • Bar Association of San Francisco
  • Fight for Justice Campaign
  • Society of Automotive Engineers
  • State Bar of California

  • Co-Editor in Chief, “ABA Survey of Federal Class Action Law,” 2018-present
  • Lead Author, “Citizen Report on Utility Terrain Vehicle (UTV) Hazards and Urgent Need to Improve Safety and Performance Standards; and Request for Urgent Efforts To Increase Yamaha Rhino Safety and Avoid Needless New Catastrophic Injuries, Amputations and Deaths,” Lieff Cabraser Heimann & Bernstein, LLP, 2009
  • Executive Editor and Co-Author, “Decisions Interpreting California’s Rules of Class Action Procedure,” Survey of State Class Action Law (ABA 2000 – present), updated and republished in 5 Newberg on Class Actions (2001 – present)
  • Co-Editor, “California Class Actions Practice and Procedures, ” 2003 – 2006
  • Coordinating Editor and Co-Author of California section of the ABA State Class Action Survey, 2001 – 2014
  • Co-Author with Elizabeth J. Cabraser, “Class Actions Fairness Act of 2005″” California Litigation, Vol. 18, No. 3, 2005
  • Co-Author, Introduction, “Sanctioning Discovery Abuses in the Federal Court,” LRP Publications, 2000
  • Author, “AHP Loses Key California Motion In Limine,” February 2000
  • “With Final Approval, Diet Drug Class Action Settlement Avoids Problems That Doomed Asbestos Pact,” Leader Publications, 2000
  • Co-Author, “The Shareholder Strikes Back: Varied Approaches to Civil Litigation Claims are Available to Help Make Shareholders Whole,” Mealey’s Emerging Securities Litigation Reporter, September 2002
  • Co-Author, “Ethics and Admissibility: Failure to Disclose Conflicts of Interest in and/or Funding of Scientific Studies and/or Data May Warrant Evidentiary Exclusions,” Mealey’s December Emerging Drugs Reporter, December 2002
  • Co-Editor-In-Chief, “Fen-Phen Litigation Strategist,” Leader Publications, 1998 – 2000
  • Author, “Off-Label Drug Promotion Permitted,” October 1999
  • Co-Author, “The Future of Prescription Drug Products Liability Litigation in a Changing Marketplace,” and “Six Courts Certify Medical Monitoring Claims for Class Treatment,” 29 Forum 4 (Consumer Attorneys of California), 1999
  • Co-Author, “Class Certification of Medical Monitoring Claims in Mass Tort Product Liability Litigation,” ALI-ABA Course of Study, 1999
  • Co-Author, “How Class Proofs of Claim in Bankruptcy Can Help in Medical Monitoring Cases,” Leader Publications, 1999
  • Author, “Special Master Rules Against SmithKline Beecham Privilege Log,” November 1999

  • Selected for inclusion by peers in The Best Lawyers in America in fields of “Mass Tort Litigation/Class Actions – Plaintiffs,” “Product Liability Litigation – Plaintiffs” and “Personal Injury Litigation – Plaintiffs,” 2012 – 2025
  • “Lawdragon 500 Leading Plaintiff Consumer Lawyers in America,” Lawdragon, 2023, 2024
  • “Super Lawyer for Northern California,” Super Lawyers, 2006-2023
  • “Outstanding Subcommittee Chair for the Class Actions & Derivative Suits,” ABA Section of Litigation, 2013
AAJ Founders Circle 2024